journal article·2026-02Open access

NARFL Knockout Triggers Ferroptosis‐Driven Vascular Endothelial Dysfunction

Hui Hu, Jing Luo, Li Yu, Daoxi Qi, Boyu Li, Yating Chen, Chen Wang, Xiaokang Zhang, Wenzheng Guo, Qiyong Lou, Gang Zhai, Yonglin Ruan, Jianfei Huang, Shengchi Shi, Zhan Yin, Fang Zheng

Advanced Science· Volume 13· Issue 8

Abstract

Abstract Nuclear prelamin A recognition factor‐like (NARFL) is a core component of the cytosolic iron‐sulfur (Fe‐S) protein assembly (CIA) system. Yet, its role in vascular pathophysiology remains poorly defined. This study demonstrates that NARFL deficiency triggers ferroptosis, leading to severe vascular endothelial dysfunction across species. In zebrafish, narfl knockout causes embryonic lethality, accompanied by neurovascular defects, blood‐brain barrier disruption, and aberrant hemodynamics. Similarly, knockout of the murine ortholog (Ciao3) results in mid‐gestational embryonic lethality due to impaired vascular development and endothelial progenitor cell maturation. Mechanistically, NARFL deficiency disrupts CIA complex assembly, compromising Fe‐S cluster transfer to client apo‐proteins and leading to a functional shift of cytosolic aconitase (ACO) to iron regulatory protein 1 (IRP1), causing iron overload, heightened oxidative stress, and lipid peroxidation. Consequently, key anti‐ferroptotic defenses are suppressed, culminating in endothelial ferroptosis. This pathway is conserved in human endothelial cells, where NARFL deficiency recapitulates the ferroptotic phenotype and functional impairments, which are rescued by the ferroptosis inhibitor. Clinically, specific NARFL polymorphisms have been identified as conferring susceptibility to vascular endothelial disorders (pulmonary hypertension, epilepsy, and neurodegenerative diseases). The work unveils a novel CIA‐ferroptosis‐vascular axis, positioning NARFL as a critical guardian of endothelial health and a potential therapeutic target.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Metalloenzymes and iron-sulfur proteins · Iron Metabolism and Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Gene Diagnosis and Department of Clinical Laboratory Medicine Zhongnan Hospital of Wuhan University Wuhan Hubei 430071 China

Department of Laboratory Medicine Shanghai East Hospital Tongji University School of Medicine Shanghai 200123 China

State Key Laboratory of Freshwater Ecology and Biotechnology Institute of Hydrobiology Chinese Academy of Sciences Wuhan Hubei 430072 China

Funding

National Natural Science Foundation of China · Zhongnan Hospital of Wuhan University · Shanghai Rising-Star Program

References (56)

Show source-provided references
1. 10.1038/s41594-020-0454-010.1038/s41594-020-0454-0 ↗
2. 10.1074/jbc.M112.41660210.1074/jbc.M112.416602 ↗
3. 10.1074/jbc.R117.78953710.1074/jbc.R117.789537 ↗
4. Lill R. · Molecular Cell Research · 2015 · 1853 · 1251
5. 10.1016/j.bbamcr.2020.11884710.1016/j.bbamcr.2020.118847 ↗
6. 10.1016/j.bbamcr.2020.11886310.1016/j.bbamcr.2020.118863 ↗
7. 10.1016/j.ejcb.2015.05.00310.1016/j.ejcb.2015.05.003 ↗
8. 10.1074/jbc.M112.43127010.1074/jbc.M112.431270 ↗
9. 10.1126/science.121966410.1126/science.1219664 ↗
10. 10.1074/jbc.M110.20173110.1074/jbc.M110.201731 ↗
11. 10.3390/ijms2203127810.3390/ijms22031278 ↗
12. 10.1074/jbc.M11028220010.1074/jbc.M110282200 ↗
13. 10.3390/ijms23181074010.3390/ijms231810740 ↗
14. 10.18632/oncotarget.1315610.18632/oncotarget.13156 ↗
15. 10.1016/j.nbd.2018.06.02210.1016/j.nbd.2018.06.022 ↗
16. 10.2174/187152731766618082812182010.2174/1871527317666180828121820 ↗
17. 10.1016/j.redox.2019.10135510.1016/j.redox.2019.101355 ↗
18. 10.1016/j.molcel.2018.10.04210.1016/j.molcel.2018.10.042 ↗
19. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
20. 10.1172/JCI13645910.1172/JCI136459 ↗
21. 10.1016/j.ccell.2019.04.00210.1016/j.ccell.2019.04.002 ↗
22. 10.1016/j.freeradbiomed.2022.01.02010.1016/j.freeradbiomed.2022.01.020 ↗
23. 10.1007/s11427-022-2313-110.1007/s11427-022-2313-1 ↗
24. 10.1152/physrev.00050.201710.1152/physrev.00050.2017 ↗
25. 10.1016/j.celrep.2021.10925510.1016/j.celrep.2021.109255 ↗
26. 10.1074/jbc.271.7.346010.1074/jbc.271.7.3460 ↗
27. 10.1194/jlr.M00306110.1194/jlr.M003061 ↗
28. 10.2133/dmpk.20.47810.2133/dmpk.20.478 ↗
29. 10.3390/ijms2404338310.3390/ijms24043383 ↗
30. 10.1016/j.yjmcc.2018.08.02710.1016/j.yjmcc.2018.08.027 ↗
31. 10.1091/mbc.E12-09-064810.1091/mbc.E12-09-0648 ↗
32. 10.1172/JCI4037210.1172/JCI40372 ↗
33. 10.1093/hmg/ddaa17210.1093/hmg/ddaa172 ↗
34. 10.1161/CIRCULATIONAHA.118.03588910.1161/CIRCULATIONAHA.118.035889 ↗
35. 10.1042/BJ2006063510.1042/BJ20060635 ↗
36. 10.1038/nchembio87210.1038/nchembio872 ↗
37. 10.1038/sj.emboj.760021610.1038/sj.emboj.7600216 ↗
38. 10.1016/j.jbc.2022.10209410.1016/j.jbc.2022.102094 ↗
39. 10.1186/s13578-018-0239-x10.1186/s13578-018-0239-x ↗
40. 10.1038/nature0447910.1038/nature04479 ↗
41. 10.1016/j.redox.2021.10185410.1016/j.redox.2021.101854 ↗
42. 10.1242/dev.19951210.1242/dev.199512 ↗
43. 10.1038/s41586-022-04804-z10.1038/s41586-022-04804-z ↗
44. 10.1017/S096719942000017910.1017/S0967199420000179 ↗
45. 10.1093/humupd/7.2.17510.1093/humupd/7.2.175 ↗
46. 10.1002/mrd.108028040810.1002/mrd.1080280408 ↗
47. 10.1161/ATVBAHA.117.30981310.1161/ATVBAHA.117.309813 ↗
48. 10.2147/IJN.S25539210.2147/IJN.S255392 ↗
49. 10.1016/j.ccc.2019.12.00910.1016/j.ccc.2019.12.009 ↗
50. 10.1016/j.ymgme.2023.10766810.1016/j.ymgme.2023.107668 ↗
51. 10.1186/s13293-023-00534-710.1186/s13293-023-00534-7 ↗
52. 10.1002/aja.100203030210.1002/aja.1002030302 ↗
53. 10.1038/nature0557710.1038/nature05577 ↗
54. C.Moens CSH protocols2008 3 pdb. prot5037.
55. C.Moens CHS protocols2008 3 pdb.prot5038.
56. 10.2144/00011261910.2144/000112619 ↗